NuGene International, Inc.’s subsidiary corporation, NuGene BioPharma, Inc., has acquired all rights, title and interest in and to SkinGuardian®, an FDA-approved (monographed) skin protectant, antiseptic, and moisturizing topical cream.

NuGene BioPharma acquired all intellectual property held by SkinGuardian and its founder and owner, Chris O’Brien, relating to the SkinGuardian technology and applications. This includes the patent under which the technology is protected, the company trademark, all formulas and derivatives under the patent, clinical trial data, and any and all other rights, title and interest in and to the SkinGuardian product. Under the agreement, O’Brien will provide ongoing consultation to NuGene International, Inc.

“As stated previously, NuGene’s stem cell technologies and applications extend beyond the cosmeceutical and hair care market, the focus of NuGene International,” explained NuGene International’s CEO Ali Kharazmi when announcing the acquisition. “We decided to form NuGene BioPharma in order to develop and market FDA-approved products that have pharmacological properties that can enhance the healing of wounds and skin conditions.”

SkinGuardian provides an antimicrobial composition that may be used against a wide variety of microorganisms including bacteria, fungi, prions and viruses. It serves as an effective guard for damaged and/or undamaged skin, and as an effective guard against infections. The antimicrobial composition has proved to be effective against viruses, and more specifically, enveloped and non-enveloped viruses.

“We see this FDA-approved topical cream as the foundation for a variety of topical treatments we will be developing that incorporate the use of stem cells to enhance healing,” Kharazmi continued. “This is a prime example of the type of synergistic acquisitions we intend to make that will expand our range of opportunities while significantly reducing our time to market.”